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Abstract 125I-labeled botulinum type B neurotoxin was shown 
to bind specifically to recombinant rat synaptotagmins I and II. 
Binding required reconstitution of the recombinant proteins with 
gangliosides Gxlb/GD1,. Scatchard plot analyses revealed a single 
class of binding site with dissociation constants of 0.23 and 2.3 
nM for synaptotagmin II and synaptotagmin I, respectively, val- 
ues very similar to those of the high- (0.4 nM) and low-affinity 
(4.1 nM) binding sites in synaptosomes. The high-affinity binding 
of neurotoxin to synaptosomes was specifically inhibited by a 
monoclonal antibody recognizing with the amino-terminal region 
of synaptotagmin II. These results suggest that this region of 
synaptotagmin II participates in the formation of the high-affinity 
toxin binding site by associating with specific gangliosides. 
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1. Introduction 
Clostridium botul&um neurotoxin acts preferentially on nerve 
endings to inhibit neurotransmitter release [1]. The neurotoxin 
is classified into seven serotypes (A-G), each having a similar 
structure and mechanism of action [2,3]. They are cleaved by 
limited proteolysis to yield heavy and light chains held together 
by a disulfide bond. Toxin action has been proposed to involve 
a series of events, including binding to a type-specific receptor 
via the heavy chain, penetration through the membrane by 
receptor-mediated endocytosis, and the subsequent pH-in- 
duced translocation of the light chain into the neuronal cytosol 
[4]. Recent studies have demonstrated that the light chain is a 
zinc-dependent endopeptidase and specifically cleaves proteins 
involved in synaptic vesicle exocytosis [5,6]. Although the bind- 
ing of the neurotoxin to the presynaptic membrane is an oblig- 
atory initial step, the receptor has not clearly identified. 
Recently we have purified 58 kDa protein from rat brain 
synaptosomes, to which type B neurotoxin (BoNT/B) binds 
only in the presence of ganglioside GTI b or Gola [7]. Partial 
amino acid sequences of the 58 kDa protein were identical to 
those of synaptotagmin [7], an integral membrane protein of 
synaptic vesicles [8,9]. These results suggest that synaptotagmin 
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associated with gangliosides may be the receptor for BoNT/B. 
In the present study, we found that recombinant synaptotagmin 
II associated with gangliosides forms high-affinity toxin bind- 
ing site located in an amino-terminal domain. 
2. Materials and methods 
2.1. Materials 
BoNT/B was purified as described [10] and iodinated with Nat2~I 
(DuPont-NEN) by the chloramine-T method [11]. The specific activity 
of [~25I]BoNT/B was 3 to 4 mCi/mg of protein, and the residual toxicity 
was about 80% of that of the unlabeled toxin before labeling. The heavy 
and light chains of BoNT/B were separated as described [12]. Rat brain 
synaptosomes were prepared as described [7]. The 58-kDa protein re- 
ceptor for BoNT/B was purified from the synaptosomes [7]. Rabbit 
polyclonal antibodies against a synthetic peptide corresponding to 
amino-terminal 20amino acid residues of rat synaptotagmins I and I1 
(PAbs StglN and Stg2N) were generated as described [13]. Gangli- 
osides, GMI , GM3 , GD3 , GDla, GDlb, and GTI b were purchased from 
Iatron Laboratories. A ganglioside mixture was prepared from mouse 
brains [14]. 
2.2. Preparation of recombinant synaptotagmin 
Recombinant rat synaptotagrnin expression plasmid was used to 
transform E. coli BL21(DE3)pLysS [7]. The recombinant proteins were 
prepared by solubilization with 20 mM MEGA-9 (Dojindo) from inclu- 
sion bodies after induction with isopropyl-l-thio-fl-D-galactopyra- 
noside. The amount of recombinant synaptotagmin I and II in the 
MEGA-9 extract was estimated by scanning and integrating after SDS- 
PAGE and Coomassie blue staining (- 6% for synaptotagmin I and - 10% 
for synaptotagmin II). 
2.3. BoNT/B binding experiments 
The solubilized recombinant synaptotagmin was incorporated into 
phosphatidylcholine lipid vesicles by an acetone precipitation method 
as described previously [7,15]. The binding of [~zsI]BoNT/B to the re- 
constituted lipid vesicles and synaptosomes was measured by a filtra- 
tion assay as described [15]. Scatchard analysis of the binding data was 
performed by the computer program SP123 [16]. 
2.4. Dot-blot assay 
Individual ganglioside (0.5/.tg of NeuAc in 1/ll) dissolved in metha- 
nol was spotted on PVDF membrane according to the method of 
Chabraoui et al. [17]. The membranes were washed with HBS (3 mM 
HEPES-NaOH buffer, pH 7.0, containing 0.12 M NaCI, 2.5 mM KC1, 
2 mM MgClz, and 2 mM CaC10 and blocked with HBS containing 5% 
skimmed milk. The membranes were then treated for 2 h with the 
recombinant synaptotagmin (10/~g of protein/ml) diluted in HBS con- 
taining 1% skimmed milk and 10 mM MEGA-9. After washing, the 
synaptotagmin which had bound to gangliosides was reacted with mAb 
and subsequently with goat anti-mouse IgG conjugated with alkaline 
phosphatase. The immunoreactive spots were visualized with the Pro- 
toBlot Color Development System (Promega). In order to determine 
whether BoNT/B reacts directly to the complex of synaptotagmin a d 
ganglioside, the membranes pretreated with synaptotagmin were incu- 
bated with [IzSI]BoNT/B (1 nM) for 1 h. The membranes were washed 
and exposed to Kodak X-Omat film with an intensifying screen at 
-80°C. 
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Fig. 1. Detection of synaptotagmins I and II in purified BoNT/B recep- 
tor. The purified BoNT/B receptor was subjected to SDS-PAGE (1 
pg/lane, 12.5% gel) under reducing conditions followed by silver stain- 
ing (lane 1) and by immunoblotting probed with antibodies against 
synaptotagmins I (PAb StglN, lane 2) and II (PAb Stg2N, lane 3). The 
positions of molecular mass standards are shown on the left. 
2.5. Preparation of monoclonal ntibodies 
A synthetic peptide (MRNIFKRNQEPIVAPATTTA-(C)) corre- 
sponding to the N-terminus of rat synaptotagmin II was coupled to 
keyhole limpet hemocyanin and used for the immunization of BALB/c 
mice. Hybridomas were generated as described [18]. Antibody produc- 
tion by hybridomas was examined by ELISA with the synthetic peptide. 
A single hybridoma line (8G2b) was established. 
A mAb, designated as ST209, against recombinant synaptotagmin II 
was prepared as before [7]. Prior to immunization, the recombinant 
synaptotagmin II was partially purified by immunoaffinity chromatog- 
raphy on CNBr-Sepharose 4B coupled with mAb 8G2b. Antibody 
production by hybridomas was examined by ELISA [19] with the syn- 
thetic peptide and immunoblotting. 
The mAbs were purified from the ascitic fluid by affinity chromatog- 
raphy on Affi-Gel Protein A (Bio-Rad). The subclasses of the mAbs 
8G2b and ST209 were G] and Gza, respectively. 
2.6. Epitope mapping with synthetic peptides 
Overlapping octapeptides of synaptotagmin lI were synthesized co- 
valently bound to plastic pins with the Multipin Peptide Synthesis 
System (Chiron Mimotopes) according to the manufacturer's instruc- 
tions. The solid phase-linked peptides were incubated with mAbs and 
the binding was detected by ELISA using rabbit anti-mouse IgG conju- 
gated with horseradish peroxidase (Zymed) and ABTS as substrate. 
2.7. Other methods 
SDS-PAGE was performed by the method of Laemmli [20]. For 
immunoblotting, samples were transferred to PVDF membrane [21] 
and immunoreactive bands were detected as described [7]. Protein was 
measured by the method of Bradford [22] using bovine ),-globulin as 
a standard. The quantity of gangliosides was defined by the amount of 
NeuAc, determined by the method of Svennerholm [23]. 
3. Results 
Immunoblotting of the purified BoNT/B receptor with 
isoform specific antibodies, indicated that the 58-kDa protein 
band contained not only synaptotagmin I but also synaptotag- 
min II (Fig. 1). In order to examine whether BoNT/B really 
interacts with synaptotagmin I and II, the binding assay was 
performed using the solubilized recombinant rat synaptotag- 
min I or II expressed in E. coli. Recombinant synaptotagmins 
showed toxin-binding activity only when ganglioside mixture 
was incorporated together into lipid vesicles (Fig. 2A). BoNT/B 
binding was also observed on the lipid vesicles in the presence 
of gangliosides GTI b and GD]a, but not the other gangliosides 
(GMI, GM3, GD3, and GDlb) (data not shown). [~25I]BoNT/B 
bound to recombinant synaptotagmin I and II incorporated 
into lipid vesicles in the presence of a ganglioside mixture in a 
concentration-dependent and saturable manner (Fig. 2A). No 
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Fig. 2. Binding of [125I]BoNT/B to recombinant rat synaptotagmin associated with gangliosides. (A) Dose dependence of [1251]BoNT/B binding to 
synaptotagmin I (circles) and II (triangles) incorporated into lipid vesicles with (closed symbols) or without (open symbols) gangliosides. The 
solubilized recombinant synaptotagmin (60 ng protein) reconstituted into lipid vesicles with or without a ganglioside mixture (15 ng NeuAc) was 
incubated at 37°C for 1 h with increasing concentrations of [~25I]BoNT/B. Specific toxin binding per mg of synaptotagmin was plotted after correction 
for nonspecific binding measured in the presence of a 1,000-fold excess of unlabeled toxin. Values are the mean +_ S.E. from three experiments. Error 
bars smaller than the symbols were omitted. (B) Scatchard plot of the binding data in the presence of gangliosides shown in A. 
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Fig. 3. Binding of [~251]BoNT/B to the complex of synaptotagmin a d 
gangliosides formed on PVDF membranes. After treatment of gangli- 
osides (0.5 pg of NeuAc) spotted on the membranes with synaptotag- 
min II (panel II) for 1 h at room temperature, [125I]BoNT/B (1 nM) was 
incubated for 1 h in the absence (middle) or presence (right) of excess 
of unlabeled toxin. The synaptotagmin which had bound to gangli- 
osides was probed with mAb 8G2b (left). The MEGA-9 extract of 
E. coli transformed with vector (pET-3a) alone was used as a control 
(panel C). 
binding was observed in lipid vesicles containing angliosides 
without the recombinant protein (data not shown). Interest- 
ingly, Scatchard plot analyses indicated a single class of binding 
site with the dissociation constants (Kd) of 2.3 and 0.23 nM for 
synaptotagmins I and II, respectively (Fig. 2B). [125I]BoNT/B 
binding to the reconstituted lipid vesicles was effectively inhib- 
ited by the heavy chain but not by the light chain of BoNT/B 
(data not shown). Previously, we have demonstrated that the 
58-kDa protein fraction and brain synaptosomes contain two 
classes of binding site for BoNT/B [7,15]. These results uggest 
that synaptotagmins I and II contribute to the formation of the 
low- and high-affinity BoNT/B binding sites, respectively. 
In order to confirm that the synaptotagmin/ganglioside com-
plex could be recognized by BoNT/B without reconstitution 
into lipid vesicles, the direct interaction of the neurotoxin and 
synaptotagmins with gangliosides on PVDF membranes was 
examined (Fig. 3). Synaptotagmin II bound to all the gangli- 
osides tested, suggesting that there was no restricted selectivity. 
However, [~25I]BoNT/B was found to react only with spots of 
the ganglioside mixture, GDLa, and Gv~b which had been pre- 
treated with synaptotagmin II. The radioactive spots were not 
observed in the presence of an excess of unlabeled toxin, sug- 
gesting that the interaction of [~25I]BoNT/B to the complex of 
synaptotagmin a d ganglioside was specific. 
The two mAbs (8G2b and ST209) obtained in this experi- 
ment specifically reacted with rat synaptotagmin II in im- 
munoblots and with the synthetic amino-terminal 20 amino 
acid peptide in the ELISA (data not shown). The binding of 
[J25I]BoNT/B to synaptosomes was inhibited by mAb ST209 in 
a concentration dependent manner, whereas mAb 8G2b 
showed no inhibitory effect (Fig. 4). These results suggest that 
BoNT/B associates with the amino-terminal region of synapto- 
tagmin II, probably within 20 amino acids from the amino- 
terminus. These results predict hat mAb ST209 should inhibit 
[t25I]BoNT/B binding only to the high-affinity binding site in 
synaptosomes. Thus we conducted binding experiments with 
synaptosomes in the presence of the concentration (50 pg/ml) 
of mAb ST209 that produced 50% inhibition of the total bind- 
ing. The capacity of the high affinity binding decreased toabout 
50% while the K a was not modified. Neither of the capacity nor 
the Ka with the low affinity binding sites was affected by this 
treatment (Fig. 5). To delineate the respective epitopes of mAbs 
8G2b and ST209, we designed 18 successive octapeptides ach 
offset by one amino acid residue from Arg 2 to Pro 26 and exam- 
ined their immunoreactivities with mAbs 8G2b and ST209. As 
shown in Fig. 6, the reactivities of the two mAbs with their 
synthetic octapeptides overlapped partially. However, mAb 
ST209 strongly reacted with the peptides containing the se- 
quence 9QEPIVA 14, whereas mAb 8G2b bound preferentially 
to the peptides having the sequence 7RNQE~°. The results indi- 
cate that the epitope recognizing mAb ST209 is located close 
to that of mAb 8G2b in the amino terminal region of synapto- 
tagmin II. 
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BoNT acts through a series of events, the first of which is the 
binding to cell surface receptors. The identity of these receptors 
and their role in neuronal function have not been clearly dem- 
onstrated. We have previously obtained evidence that the pro- 
tein receptor for BoNT/B may be synaptotagmin I [7]. The 
present data indicate that not only synaptotagmin I but also 
synaptotagmin II interacts with BoNT/B in the presence of 
gangliosides, although they display different binding affinities. 
The dissociation constants of synaptotagmins I and II are com- 
parable to those of the low- and high-affinity binding sites 
respectively in rat brain synaptosomes, and the 58-kDa protein 
fraction purified from synaptosomes [7,15,24]. In fact synapto- 
tagmin II was also detected in the 58-kDa protein fraction by 
immunoblotting. Thus, it is probable that the low-and high- 
affinity sites in rat synaptosomes correspond to synaptotag- 
mins I and I1. Direct binding experiments with gangliosides 
spotted onto membranes revealed that BoNT/B only binds to 
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Fig. 4. Inhibition of [~25I]BoNT/B binding to synaptosomes by mAbs 
recognizing the amino-terminal region of synaptotagmin lI. [~25I]BoNT/ 
B (0.25 nM) was incubated at 37°C for 1 h with synaptosomes (10 pg 
of protein) in the presence of mAbs ST209 (o) and 8G2b (©). Specific 
toxin binding was determined by subtracting the nonspecific binding 
measured in the presence of excess unlabeled toxin. Each point repre- 
sents the mean _+ S.E. from three experiments. The [~25I]BoNT/B bound 
to synaptosomes in the absence of mAb was considered as 100%. 
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Fig. 5. Effect ofmAb ST209 on [~251]BoNT/B binding to the high- affinity site. [~2SI]BoNT/B binding to synaptosomes was determined in the presence 
(A) or absence (B) ofmAb ST209 (50 pg/ml) as described in Fig. 2. The data are displayed as a Scatchard plot. Each point represents he mean from 
three experiments. Inset: the Kd and binding capacity (Bma0 of the toxin binding site. 
a complex consisting of synaptotagmin a d gangliosides GDI  a 
o r  GT1 b. 
Synaptotagmin s highly conserved among a wide range of 
animal species and considered to be involved in Ca2+-dependent 
exocytosis of synaptic vesicles at the nerve terminal [25,26]. The 
homology between synaptotagmin I and II is not uniformly 
distributed across the molecule, and is highest in the carboxyl- 
terminal cytoplasmic C2 domains (88% sequence identity) and 
lowest in the amino-terminal regions (46% identity) [27]. The 
lower homology in the amino-terminal regions may confer the 
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Fig. 6. Immunoreactivity of mAbs ST209 and 8G2b with octapeptides 
from the amino-terminal region of synaptotagmin II. Overlapping pep- 
tides were synthesized in a pin-bound form (amino acid sequences are 
shown on the left of the figure) were reacted with mAb 8G2b (0.2/zg/ml, 
open bar) and ST209 (1 pg/ml, closed bar) for 1 h at room temperature. 
After washing, the bound mAbs were detected with rabbit anti-mouse 
IgG conjugated with horseradish peroxidase and ABTS as a substrate. 
The amino acid sequence of the amino-terminal region (residues 1 26) 
is shown on the top of the figure. The amino acid sequences common 
to each of the immunoreactive p ptides are boxed. 
difference in the affinities of the two isoforms for BoNT/B. 
Synaptotagmin has a single transmembrane region and short 
amino-terminal domain located in the intravesicular space [28]. 
However the amino-terminal domain is exposed at the outside 
of the nerve terminal after synaptic vesicle exocytosis [13], 
which is compatible with the hypothesis that the amino-termi- 
nal region of synaptotagmin constitutes a part of BoNT/B re- 
ceptor. In order to address the question, we examined the 
inhibitory effect of anti-synaptotagmin II antibodies on the 
toxin binding to synaptosomes. Of two mAbs (8G2b and 
ST209) recognizing 20 amino acid synthetic peptides from the 
amino-terminus, only mAb ST209 inhibited the toxin binding 
with high affinity. This mAb was subsequently shown to react 
with the octapeptides including homologous equence from 
Gln 9 to Ala ~4. These findings support he idea that the amino- 
terminal region of synaptotagmin II, by association with gangli- 
osides GTlb/GDla, forms the high-affinity binding site for BoNT/ 
B. The precise structure of the complex of synaptotagmin a d 
gangliosides acting as BoNT/B receptors remains to be estab- 
lished. More recently, eDNA clones encoding other synapto- 
tagmins (III through VIII) have been isolated one after another 
[29-32]. It is now in progress to determine whether these novel 
isoforms of synaptotagmin teract with BoNT/B and other 
BoNTs. 
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